IND

IND. An investigational new drug application filed with the FDA as more fully defined in 21 C.F.R. § 312.3

IND. An Investigational New Drug Application filed with the FDA to begin clinical studies of a new drug in humans (pursuant to 21 CFR 312, et. seq., as amended).

IND. An Investigational New Drug Application filed with the FDA to begin clinical studies of a new drug in humans (pursuant to 21 CFR 312, et. seq., as amended), and/or the corresponding application with a corresponding regulatory agency in a country other than the United States, as applicable, and/or any successor application (s)

IND. An investigational new drug application, as described in 21 C.F.R. Section 312.23, filed for purposes of conducting clinical trials in accordance with the requirements of the United States Food, Drug and Cosmetic Act of 1938, as amended, and the rules and regulations promulgated thereunder, including all supplements and amendments thereto relating to the use of the Licensed Product, ownership of which shall be transferred to Teva by Rexahn upon and subject to issuance of the License Notice.

IND. An Investigational New Drug application filed with the FDA and any equivalent foreign filing

IND. An Investigational New Drug application for Bulk Drug Substance, as defined in the FD&C Act or FDA Regulations (21 CFR 314).

IND. An Investigational New Drug application for Product, as defined in the FD&C Act or FDA Regulations (21 CFR)

IND. Means an Investigation New Drug application or any comparable application required by a Foreign Jurisdiction filed for the Product by CLIENT with the FDA and all subsequent submissions, supplements or amendments related thereto.

IND. An investigational new drug application submitted to the FDA.

IND. Means an Investigational New Drug application, as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, for initiating clinical trials in the United States.